Relay: Virtual Analyst and Investor Event Eyes Cholangiocarcinoma, Breast Cancer

 End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (CCA) to potentially support accelerated approval

Interim data from the once daily (QD) dosing schedule shared with the FDA demonstrated confirmed partial responses in eight out of thirteen (62%) FGFRi-naïve FGFR2-fusion CCA patients, including all four of the patients treated at the registrational trial dose of 70 mg QD

Relay Therapeutics discloses three new programs as part of a growing HR+/HER2- breast cancer franchise: selective CDK2 inhibitor, ERα degrader, and chemically distinct pan mutant-PI3Kα (RLY-5836)

Relay Therapeutics continues to expect its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into 2025

https://finance.yahoo.com/news/relay-therapeutics-discloses-anticipated-registrational-100000172.html